Bioerodible devices for intermittent release of simvastatin acid

International Journal of Pharmaceutics

Volumn 340, Issue 1-2, 2007, Pages 6-12

  Jeon, Ju Hyeong ^a   Thomas, Mark V ^b   Puleo, David A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY COLLEGE OF DENTISTRY   (United States)

Author keywords

CAP PF 127 system; Controlled release; Intermittent release; Pulsatile release; Simvastatin acid

Indexed keywords

ACETONE; ALKALINE PHOSPHATASE; CELLACEFATE; DNA; HYDROXYACID; MICROSPHERE; OIL; OSTEOCALCIN; POLOXAMER; SIMVASTATIN; WATER;

ANIMAL CELL; ARTICLE; BIOERODIBLE DEVICE; BONE DEVELOPMENT; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; DNA CONTENT; DRUG DELIVERY SYSTEM; DRUG INTERMITTENT RELEASE; DRUG SOLUBILITY; EMULSION; ENZYME ACTIVITY; EROSION; HIGH TEMPERATURE PROCEDURES; LACTONE RING OPENING; MOUSE; NONHUMAN; OSSIFICATION; PRESSURE; PRIORITY JOURNAL; PROTEIN SECRETION; PULSATILE DRUG RELEASE; RING OPENING; SINTERING; ULTRAVIOLET RADIATION;

3T3 CELLS; ACETONE; ALKALINE PHOSPHATASE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; EMULSIONS; KINETICS; MICE; MICROSPHERES; OILS; OSTEOBLASTS; OSTEOCALCIN; POLOXAMER; SIMVASTATIN; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 34447284555     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.03.007     Document Type: Article

References (33)

1. Agrawal C.M., Niederauer G.G., Micallef D.M., and Athanasiou K.A. The use of PLA-PGA polymers in orthopaedics. In: Wise D.D., Trantolo D.J., Altobelli D.E., Gresser J.D., and Yaszemski M.J. (Eds). Encyclopedic Handbook of Biomaterials and Bioengineering (1995), Marcel Dekker, New York 2018-2115
2. Bergsma E.J., Rozema F.R., Bos R.R., and Bruijn W.C. Foreign body reactions to resorbable poly(L-lactide) bone plates and screws used for the fixation of unstable zygomatic fractures. J. Oral Maxillofac. Surg. 51 (1993) 66-170
3. Boyce T., Edwards J., and Scarborough N. Allograft bone: the influence of processing on safety and performance. Orthop. Clin. North Am. 30 (1999) 571-581
4. Casey P.J., and Seabra M.C. Protein prenyltransferases. J. Biol. Chem. 271 (1996) 5289-5292
5. Chan K.A., Andrade S.E., Boles M., Buist D.M.S., Chase G.A., Donahue J., Goodman M., Gurwitz J., LaCroix A., and Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 24 (2000) 2185-2188
6. Corsini A., Maggi F.A., and Catapano A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res. 31 (1995) 9-27
7. Daniels A.U., Taylor M.S., Andriano K.P., and Heller J. Toxicity of absorbable polymers proposed for fracture fixation devices. Proc. Orthop. Res. Soc. 17 (1992) 88
8. Daniels A.U., Taylor M.S., Heller J., and Andriano K.P. Six bioabsorbable polymers: in vitro acute toxicity of accumulated degradation products. J. Appl. Biomater. 5 (1994) 151-157
9. Davignon J., and Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr. Opin. Lipidol. 10 (1999) 543-559
10. Edwards C.J., Hart D.J., and Spector T.D. Oral statins and increased bone mineral density in postmenopausal women. Lancet 355 (2000) 2219-12219
11. Gates K.A., Grad H., Birek P., and Lee P.I. A new bioerodible polymer insert for the controlled release of metronidazole. Pharm. Res. 11 (1994) 1605-1609
12. Hamelin B.A., and Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19 (1998) 26-37
13. Istvan E., and Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292 (2001) 1160-1164
14. Kaesemeyer W.H., Caldwell R.B., Huang J., and Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J. Am. Coll. Cardiol. 33 (1999) 234-241
15. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D., Sessa W., and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6 (2000) 1004-1010
16. Labarca C., and Paigen A. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 102 (1980) 344-352
17. Lee P.I. Novel approach to zero-order drug delivery via immobilized non-uniform drug distribution in glassy hydrogels. J. Pharm. Sci. 73 (1984) 1344-1347
18. Maeda T., Matsunuma A., Kawane T., and Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 280 (2001) 874-877
19. Meir C.M., Schlienger R.G., Kraenzlin M.E., Schlegel B., and Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283 (2000) 3205-3210
20. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., and Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 286 (1999) 1946-1949
21. Popovic J.R. 1999 National Hospital Discharge Survey: annual summary with detailed diagnosis and procedure data. Vital Health Stat. 13 (2001) 1-206
22. Raiche A., and Puleo D.A. Association polymers for modulated release of bioactive proteins. IEEE Eng. Med. Biol. Mag. 22 (2003) 35-41
23. Raiche A.T., and Puleo D.A. In vitro effects of combined and sequential delivery of two bone growth factors. Biomaterials 25 (2004) 677-685
24. Roskos K.V., Tefft J.A., and Heller J. A morphine-triggered delivery system useful in the treatment of heroin addiction. Clin. Mater. 13 (1993) 109-119
25. Serajuddin A.T., Ranadive S.A., and Mahoney E.M. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 80 (1991) 830-834
26. Skoglund B., Forslund C., and Aspenberg P. Simvastatin improves fracture healing in mice. J. Bone Miner. Res. 17 (2002) 2004-2008
27. Suganuma J., and Alexander H. Biological response of intramedullary bone to poly-L-lactic acid. J. Appl. Biomater. 15 (1993) 13-27
28. Sugiyama M., Kodama T., Konishi K., Abe K., Asami S., and Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun. 271 (2000) 688-692
29. Tefft J.A., Roskos K.V., and Heller J. The effect of lipase on the release of naltrexone from triglyceride-coated cellulose acetate phthalate microspheres. J. Biomed. Mater. Res. 26 (1992) 713-724
30. Thompson G.J., and Puleo D.A. Effects of sublethal metal ion concentrations on osteogenic cells derived from bone marrow stromal cells. J. Appl. Biomater. 6 (1995) 249-258
31. Ucar M., Neuvonen M., Luurla H., Dalqvist R., Neuvonen P.J., and Mjondal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur. J. Clin. Pharmacol. 59 (2004) 879-882
32. Wang P.S., Solomon D.H., Mogun H., and Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283 (2000) 3111-3216
33. Xu X., and Lee P.I. Programmable drug delivery from an erodible association polymer system. Pharm. Res. 10 (1993) 1144-1152